American Well (AMWL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Jun, 2026Executive summary
Supplement updates the previously filed proxy statement for the 2026 Annual Meeting of Stockholders.
Shareholders are advised to read this supplement together with the original proxy statement for complete information.
Voting matters and shareholder proposals
Dr. Roy Schoenberg will not stand for re-election as a Class III director at the 2026 Annual Meeting.
The board will not nominate a substitute for Dr. Schoenberg; votes on his re-election will not be counted.
Shareholders who have already voted may change or revoke their proxy following the instructions in the proxy statement.
Board of directors and corporate governance
The board has made a determination regarding director nominations, specifically not replacing Dr. Schoenberg for the upcoming election.
Partial view of Summaries dataset, powered by Quartr API
Latest events from American Well
- Director election, auditor ratification, and executive pay were key AGM agenda items.AMWL
AGM 202616 Jun 2026 - Strong Q1 results and major government contracts position the company for profitable growth by 2027.AMWL
21st Annual Needham Technology, Media, & Consumer Conference14 May 2026 - Q1 2026 revenue fell 18%, but net loss narrowed and positive cash flow is targeted for Q4.AMWL
Q1 20266 May 2026 - Key votes include director elections, auditor ratification, and executive pay approval.AMWL
Proxy filing23 Apr 2026 - 2025 saw major cost reductions, platform innovation, and strong governance ahead of key shareholder votes.AMWL
Proxy filing23 Apr 2026 - 2026 guidance targets $195–$205M revenue, EBITDA breakeven, and strong government contract momentum.AMWL
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Margins improved and losses narrowed, with positive cash flow targeted for Q4 2026.AMWL
Q4 202512 Feb 2026 - Director elections, auditor ratification, and reverse stock split proposal advanced to vote.AMWL
AGM 20243 Feb 2026 - Q2 revenue rose to $62.8M, losses narrowed, and 2024 EBITDA guidance improved.AMWL
Q2 20242 Feb 2026